Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer

This publication has 165 references indexed in Scilit:

• Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: A 2-year, double-blind, placebo-controlled study
  Fertility and Sterility, 2004
• Cardiovascular effects of raloxifene: the arterial and venous systems
  American Heart Journal, 2004
• Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
  Oncogene, 2003
• Lignans and Tamoxifen, Alone or in Combination, Reduce Human Breast Cancer Cell Adhesion, Invasion and Migration in vitro
  Breast Cancer Research and Treatment, 2003
• Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice
  International Journal of Cancer, 2002
• Effects of Tamoxifen on the Serum Leptin Level in Patients with Breast Cancer
  Japanese Journal of Clinical Oncology, 2001
• Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary Prevention
  Annals of Surgical Oncology, 2001
• Circulating concentrations of insulin-like growth factor I and risk of breast cancer
  The Lancet, 1998
• A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
  Journal of Bone and Mineral Research, 1996
• Effects of the antiestrogen tamoxiten on low-density lipoprotein concentrations and oxidation in postmenopausal women
  The American Journal of Cardiology, 1995